Publications

Patient and physician expectation’s regarding disease and treatment of advanced HCC: the prospective PERCEPTION1 study

Auteurs: Jean-Charles Nault, Nanthara Sritharan, Gontran Verset, Ivan Borbath, Marie Lequoy, Manon Allaire, Hélène Regnault,...

Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC

Auteurs: Sayma Chaibi, Edouard Larrey, Jean Pierre Couty, Philippe Sultanik, Claudia Campani, Lorraine Blaise, Mathilde Wagner, Chantal Desdouets, Jean Charles Nault, Dominique Thabut, Manon Allaire....

Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab.

Auteurs: Claudia Campani, Ariane Vallot, Haroun Ghannouchi, Manon Allaire, Manon Evain, Philippe Sultanik, Sabrina Sidali, Lorraine Blaise, Dominique Thabut, Pierre Nahon, Olivier Seror, Nathalie Ganne-Carrié, Jean-Charles Nault, Mathilde...

No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC.

Auteurs: Francisca-Dora Copil, Claudia Campani, Marie Lequoy, Philippe Sultanik, Lorraine Blaise, Mathilde Wagner, Nathalie Ganne-Carrié, Violaine Ozenne, Dominique Thabut, Jean-Charles Nault, Vlad Ratziu, Manon Allaire. Liver...

Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: a multicentric retrospective study

Auteurs Elia Gigante, Mohamed Bouattour, José Ursic Bedoya, Hélène Regnault, Marianne Ziol, Eric Assenat, Valérie...

Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What’s new 12 months later?

Auteurs Brustia R, Bouattour M, Allaire M, Lequoy M, Hollande C, Regnault H, Blaise L,...

Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area

Auteurs Amaddeo G, Brustia R, Allaire M, Lequoy M, Hollande C, Regnault H, Blaise L,...

Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma

Auteurs Gigante E, Hobeika C, Le Bail B, Paradis V, Tougeron D, Lequoy M, Bouattour...

Publications

Patient and physician expectation’s regarding disease and treatment of advanced HCC: the prospective PERCEPTION1 study

Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC

Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab.

No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC.

Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: a multicentric retrospective study

Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What’s new 12 months later?

Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area

Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma

Pour les patients

Newsletter

Contactez nous

Publications

Patient and physician expectation’s regarding disease and treatment of advanced HCC: the prospective PERCEPTION1 study

Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC

Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab.

No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC.

Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: a multicentric retrospective study

Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area: What’s new 12 months later?

Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area

Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma

Pour les patients

Newsletter

Contactez nous

Fermer